Business Wire

WA-RUSSELL-INVESTMENTS

30.3.2021 15:29:06 CEST | Business Wire | Press release

Share
Russell Investments Enters Strategic Partnership with Hamilton Lane to Accelerate Private Markets Capabilities

Russell Investments, a leading outsourced CIO (OCIO) provider and global investment solutions firm, and Hamilton Lane (NASDAQ:HLNE), a leading private markets investment management firm, today announced a strategic partnership that will provide Russell Investments’ global clients with access to Hamilton Lane’s industry-leading private markets investment solutions, data-driven research, and innovative technology tools.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210330005696/en/

Hamilton Lane’s comprehensive private markets capabilities will further strengthen Russell Investments’ client value proposition by providing exceptional open-architecture investment solutions spanning the entire asset class spectrum. Hamilton Lane’s $90 million investment in Russell Investments further demonstrates its commitment to this strategic partnership.

“Given increasing market complexities and rising needs around financial security, fiduciaries are looking for partners that can seamlessly provide tailored, differentiated investment solutions,” said Michelle Seitz, Chairman and CEO of Russell Investments. “This partnership demonstrates our 85-year fiduciary commitment to provide comprehensive, leading-edge investment solutions and risk management to our clients. The resulting one-stop access to extensive private and public markets capabilities is, I believe, unmatched in our industry today.”

According to Seitz, institutional investors are increasingly focused on their own core business competencies and want more comprehensive relationships with strategic investment partners. The market potential is large. McKinsey & Company research reports that 76% of asset owners with assets up to $10 billion have not outsourced their investment activitiesi . Boston Consulting Group also forecasts investment solutions to be one of the fastest growing segments of the asset management industry over the next five yearsii .

Private markets are an important component of investor portfolios, and this partnership comes at a time when both private markets opportunities and allocations to the asset class continue to grow. Since 2008, capital allocated to private markets has tripled from $2.5 trillion to $7.7 trillioniii . The private markets asset class has continued to demonstrate its ability to generate meaningful returns for investors. Data from Hamilton Lane illustrates that private equity and private credit have each outperformed the MSCI World PME and the Credit Suisse Leveraged Loan PME, respectively, in 19 of the last 20 vintage yearsiiii .

“At Hamilton Lane, we are committed to providing private markets access to a broader group of investors around the world, and this partnership is another exciting development in support of that objective,” said Mario Giannini, CEO of Hamilton Lane. “We believe our investment capabilities and expertise, together with Russell Investments’ strong outsourced investment solutions, will enable enhanced and integrated access to the global private markets for Russell Investments’ clients around the world.”

Russell Investments’ clients will benefit from access to Hamilton Lane’s global investment platform and deep expertise across all private markets strategies and sectors, as well as access to Hamilton Lane’s private markets risk and portfolio construction tools. Enhanced by Hamilton Lane’s proprietary technology capabilities, Russell Investments’ Enterprise Risk Management System will allow its clients to leverage the power of an extensive open- architecture public and private markets investment platform to meet their specific goals and objectives.

For 85 years, Russell Investments has focused on improving people’s financial security. That focus aligns with Hamilton Lane’s stated purpose of providing enhanced financial well-being for those who depend on them. The two companies also share a commitment to providing exceptional client service and offering customized solutions for their global clientele.

“Russell Investments and Hamilton Lane put our clients’ needs at the center of everything we do,” said Seitz. “We are dedicated to democratizing access to the most sophisticated investment capabilities and tools in the industry. This is about extending our institutional solutions prowess, honed over decades working with the largest asset owners in the world, to more middle-market institutions and wealth management partners and their clients.”

About Russell Investments

Russell Investments is a leading outsourced CIO (OCIO) partner and global investment solutions firm providing a wide range of investment capabilities to institutional investors, financial intermediaries, and individual investors around the world. Building on an 85-year legacy of continuous innovation to deliver exceptional value to clients, Russell Investments works every day to improve the financial security of its clients. The firm is the world’s fifth-largest investment adviser, with $2.5 trillion in assets under advisement (as of 6/30/2020) and $323.7 billion in assets under management (as of 12/31/2020) for clients in 32 countries. Headquartered in Seattle, Washington, Russell Investments has offices in 19 cities around the world, including in New York, London, Tokyo, and Shanghai. For more information, please visit www.russellinvestments.com .

About Hamilton Lane

Hamilton Lane (NASDAQ: HLNE) is a leading private markets investment management firm providing innovative solutions to sophisticated investors around the world. Dedicated exclusively to private markets investing for 29 years, the firm currently employs more than 440 professionals operating in offices throughout North America, Europe, Asia Pacific and the Middle East. Hamilton Lane has approximately $657 billion in assets under management and supervision, composed of approximately $76 billion in discretionary assets and approximately $581 billion in advisory assets, as of December 31, 2020. Hamilton Lane specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors and geographies. For more information, please visit www.hamiltonlane.com or follow Hamilton Lane on Twitter: @hamilton_lane.

Cautionary Note on Forward-Looking Statements

Some of the statements in this release may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Words such as "will," "expect," "believe" and similar expressions are used to identify these forward-looking statements. Forward-looking statements discuss current expectations and projections. All forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause actual results to be materially different. You should evaluate these forward-looking statements in the context of the risks and uncertainties disclosed in Part I, Item 1A, under the heading "Risk Factors", in Hamilton Lane’s Annual Report on Form 10-K for the fiscal year ended March 31, 2020 and in its subsequent reports filed from time to time with the Securities and Exchange Commission. The forward-looking statements included in this release are made only as of the date hereof. We undertake no obligation to update or revise any forward-looking statement as a result of new information or future events, except as otherwise required by law.

Past performance is no guarantee of future results.

i Source: McKinsey and Cerulli (2020)

ii Source: Boston Consulting Group (2020 Global Asset Management report)

iii Source: Preqin.com (June 2020)

iiii Source: Hamilton Lane Data, Bloomberg (January 2021)

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye